β-血红蛋白病基因组编辑治疗的研究进展

doi:10.16288/j.yczz.17-215

遗传 ›› 2018, Vol. 40 ›› Issue (2): 95-103.doi: 10.16288/j.yczz.17-215

β-血红蛋白病基因组编辑治疗的研究进展

刘佳伟¹(),洪涛¹,秦鑫²,梁英民³,张萍¹()

1. 第四军医大学医学遗传学与发育生物学教研室，西安 710032
2. 湖北文理学院医学院，襄阳 441053
3. 第四军医大学唐都医院血液科，西安 710032

收稿日期:2017-09-28 修回日期:2017-12-18 出版日期:2018-02-20 发布日期:2018-01-11
作者简介:作者简介: 刘佳伟,本科,专业方向：生物技术。E-mail: Liujiawei1996@163.com|通讯作者: 张萍,博士,副教授,研究方向：遗传病的分子机制。E-mail: pingzhang0622@126.com
基金资助:
国家自然科学基金重大项目培育计划资助(30600492)

Recent advance on genome editing for therapy of β-hemoglobinopathies

Liu Jiawei¹(),Hong Tao¹,Qin Xin²,Liang Yingmin³,Zhang Ping¹()

1. Department of Medical Genetics and Developmental Biology, Fourth Military Medical University, Xi’an 710032, China
2. Medical College, Hubei University of Arts and Science, Xiangyang 441053, China
3. Tangdu Hospital, Fourth Military Medical Univerisy, Xi’an 710032, China

Received:2017-09-28 Revised:2017-12-18 Online:2018-02-20 Published:2018-01-11
Supported by:
the Major Program Development Project of the Natural Science Foundation(30600492)

摘要/Abstract

摘要：

β-血红蛋白病(β-hemoglobinopathies)是严重危害人类健康的6种常见疾病之一,尽管其遗传分子机制已被阐释清楚,但目前除异基因骨髓移植外尚还缺乏根治性的治疗策略。近年来,基因组编辑技术的迅速发展及其在人造血干祖细胞中的应用为β-血红蛋白病的治疗开辟了新的方向。针对血红蛋白的基因突变,可利用同源重组介导的细胞内源性DNA损伤修复途径直接修复遗传缺陷,也可以利用非同源末端连接机制沉默抑制胎儿血红蛋白表达的分子,重新激活胎儿血红蛋白的表达以缓解β-血红蛋白病人的临床症状。本文从β-血红蛋白病的基因组编辑策略及尝试、临床转化平台的要素分析等方面对该病的基因组编辑治疗的研究进展展开综述,以期为β-血红蛋白病新型治愈方案的研究以及基因组编辑技术的临床转化提供参考。

关键词: β-血红蛋白病;, 基因组编辑, 镰状红细胞贫血, β-地中海贫血;, Cas9

Abstract:

β-hemoglobinopathies are one of six groups of common illnesses affecting human health. Although the genetic mechanisms have been elucidated for several decades, curable treatment options, other than allogeneic bone marrow transplantation, are still lacking. In recent years, rapid development in genome editing technologies and their clinical applications have opened up new directions for treatment of β-hemoglobinopathies. Genome editing technologies, as applied in autologous CD34 ⁺ hematopoietic stem and progenitor cells, represents a promising remedial means for the β-globin disorders. Hemoglobin gene mutations could be corrected with homologous recombination-mediated DNA repair pathway to repair the genetic defects, while the nonhomologous end-joining pathway may be used to silence the key repressor of fetal globin expression and reactivate fetal hemoglobin expression, thereby alleviating the clinical symptoms of β-hemoglobinopathies in patients. This review summarizes the recent advances on genome editing of β-hemoglobinopathies from the bench design to the establishment of clinical translational platforms, thereby providing critical insights and references on the application of genome editing technologies for the development of therapeutic strategies for β-hemoglobinopathies.

Key words: β-hemoglobinopathies;, genome editing, sickle cell disease, β-thalassemia;, Cas9

刘佳伟,洪涛,秦鑫,梁英民,张萍. β-血红蛋白病基因组编辑治疗的研究进展[J]. 遗传, 2018, 40(2): 95-103.

Liu Jiawei,Hong Tao,Qin Xin,Liang Yingmin,Zhang Ping. Recent advance on genome editing for therapy of β-hemoglobinopathies[J]. Hereditas(Beijing), 2018, 40(2): 95-103.

参考文献

[1]	Sabath DE . Molecular diagnosis of thalassemias and hemoglobinopathies: an ACLPS critical review. Am J Clin Pathol, 2017, 148(1):6-15.
[2]	Weatherall DJ . Hemoglobinopathies worldwide: present and future. Curr Mol Med, 2008, 8(7):592-599.
[3]	Srivastava A, Shaji RV . Cure for thalassemia major-from allogeneic hematopoietic stem cell transplantation to gene therapy. Haematologica, 2017, 102(2):214-223.
[4]	Canver MC, Orkin SH . Customizing the genome as therapy for the β-hemoglobinopathies. Blood, 2016, 127(21):2536-2545.
[5]	Bauer DE, Orkin SH . Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin. Curr Opin Genet Dev, 2015, 33:62-70.
[6]	Makis A, Hatzimichael E, Papassotiriou I, Voskaridou E . 2017 Clinical trials update in new treatments of β-thalassemia. Am J Hematol, 2016, 91(11):1135-1145.
[7]	Cavazzana M, Antoniani C, Miccio A . Gene therapy for β-hemoglobinopathies. Mol Ther, 2017, 25(5):1142-1154.
[8]	Sander JD, Joung JK . CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol, 2014, 32(4):347-355.
[9]	Komor AC, Badran AH, Liu DR . CRISPR-based technologies for the manipulation of eukaryotic genomes. Cell, 2017, 168(1-2):20-36.
[10]	Qu L , Li HS , Jiang YH , Dong CS . The molecular mechanism of CRISPR/Cas9 system and its application in gene therapy of human diseases. Hereditas (Beijing), 2015, 37( 10): 974- 982.
[10]	璩良, 李华善, 姜运涵, 董春升 . CRISPR/Cas9系统的分子机制及其在人类疾病基因治疗中的应用. 遗传, 2015, 37( 10): 974- 982. [DOI]
[11]	Park CY, Kim DH, Son JS, Sung JJ, Lee J, Bae S, Kim JH, Kim DW, Kim JS . Functional correction of large factor VIII gene chromosomal inversions in hemophilia a patient-derived iPSCs using CRISPR-Cas9. Cell Stem Cell, 2015, 17(2):213-220.
[12]	Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, Binder-Scholl G, Plesa G, Hwang WT, Levine BL, June CH . Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med, 2014, 370(10):901-910.
[13]	Han YL , Li QW . Application progress of CRISPR/Cas9 genome editing technology in the treatment of HIV-1 infection. Hereditas (Beijing), 2016, 38( 1): 9- 16.
[13]	韩英伦, 李庆伟 . CRISPR/Cas9基因组编辑技术在HIV-1感染治疗中的应用进展. 遗传, 2016, 38( 1): 9- 16. doi:
[14]	Li S , Yang YY , Qiu Y , Chen YH , Xu LW , Ding QR . Applications of genome editing tools in precision medicine research. Hereditas (Beijing), 2017, 39( 3): 177- 188.
[14]	李爽, 杨圆圆, 邱艳, 陈彦好, 徐璐薇, 丁秋蓉 . 基因组编辑技术在精准医学中的应用. 遗传, 2017, 39( 3): 177- 188. [DOI]
[15]	Wang GC , Ma M , Ye YZ , Xi JZ . High-throughput functional screening using CRISPR/Cas9 system. Hereditas (Beijing), 2016, 38( 5): 391- 401.
[15]	王干诚, 马明, 叶延帧, 席建忠 . 基于CRISPR/Cas9系统高通量筛选研究功能基因. 遗传, 2016, 38( 5): 391- 401.
[16]	Hoban MD, Bauer DE . A genome editing primer for the hematologist. Blood, 2016, 127(21):2525-2535.
[17]	Hoban MD, Cost GJ, Mendel MC, Romero Z, Kaufman ML, Joglekar AV, Ho M, Lumaquin D, Gray D, Lill GR, Cooper AR, Urbinati F, Senadheera S, Zhu A, Liu PQ, Paschon DE, Zhang L, Rebar EJ, Wilber A, Wang X, Gregory PD, Holmes MC, Reik A, Hollis RP, Kohn DB . Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood, 2015, 125(17):2597-2604.
[18]	DeWitt MA, Magis W, Bray NL, Wang T, Berman JR, Urbinati F, Heo SJ, Mitros T, Mu?oz DP, Boffelli D, Kohn DB, Walters MC, Carroll D, Martin DI, Corn JE . Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Sci Transl Med, 2016, 8(360):360ra134.
[19]	Bahal R , Ali McNeer N, Quijano E, Liu YF, Sulkowski P, Turchick A, Lu YC, Bhunia DC, Manna A, Greiner DL, Brehm MA, Cheng CJ, López-Giráldez F, Ricciardi A, Beloor J, Krause DS, Kumar P, Gallagher PG, Braddock DT, Mark Saltzman W, Ly DH, Glazer PM. In vivo correction of anaemia in β-thalassemic mice by γPNA- mediated gene editing with nanoparticle delivery. Nat Commun, 2016, 7:13304.
[20]	Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, Pavel-Dinu M, Saxena N, Wilkens AB, Mantri S, Uchida N, Hendel A, Narla A, Majeti R, Weinberg KI, Porteus MH . CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature, 2016, 539(7629):384-389.
[21]	Wienert B, Funnell APW, Norton LJ, Pearson RC, Wilkinson-White LE, Lester K, Vadolas J, Porteus MH, Matthews JM, Quinlan KGR, Crossley M . Editing the genome to introduce a beneficial naturally occurring mutation associated with increased fetal globin. Nat Commun, 2015, 6:7085.
[22]	Traxler EA, Yao Y, Wang YD, Woodard KJ, Kurita R, Nakamura Y, Hughes JR, Hardison RC, Blobel GA, Li CL, Weiss MJ . A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nat Med, 2016, 22(9):987-990.
[23]	Hossain MA, Bungert J . Genome editing for sickle cell disease: a little BCL11A goes a long way. Mol Ther, 2017, 25(3):561-562.
[24]	Canver MC, Smith EC, Sher F, Pinello L, Sanjana NE, Shalem O, Chen DD, Schupp PG, Vinjamur DS, Garcia SP, Luc S, Kurita R, Nakamura Y, Fujiwara Y, Maeda T, Yuan GC, Zhang F, Orkin SH, Bauer DE . BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature, 2015, 527(7577):192-197.
[25]	Chang KH, Smith SE, Sullivan T, Chen K, Zhou QH, West JA, Liu M, Liu YC, Vieira BF, Sun C, Hong VP, Zhang MX, Yang X, Reik A, Urnov FD, Rebar EJ, Holmes MC, Danos O, Jiang HY, Tan SY . Long-term engraftment and fetal globin induction upon BCL11A gene editing in bone- marrow-derived CD34+ hematopoietic stem and progenitor cells. Mol Ther Methods Clin Dev , 2017, 4: 137-148.
[26]	Guda S, Brendel C, Renella R, Du P, Bauer DE, Canver MC, Grenier JK, Grimson AW, Kamran SC , Thornton J, de Boer H, Root DE, Milsom MD, Orkin SH, Gregory RI, Williams DA. miRNA-embedded shRNAs for lineage- specific BCL11A knockdown and hemoglobin f induction. Mol Ther, 2015, 23(9):1465-1474.
[27]	Masuda T, Wang X, Maeda M, Canver MC, Sher F, Funnell AP, Fisher C, Suciu M, Martyn GE, Norton LJ, Zhu C, Kurita R, Nakamura Y, Xu J, Higgs DR, Crossley M, Bauer DE, Orkin SH, Kharchenko PV, Maeda T . Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin. Science, 2016, 351(6270):285-289.
[28]	Renneville A, Van Galen P, Canver MC, McConkey M, Krill-Burger JM, Dorfman DM, Holson EB, Bernstein BE, Orkin SH, Bauer DE, Ebert BL . EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. Blood, 2015, 126(16):1930-1939.
[29]	Lee YT, de Vasconcellos JF, Yuan J, Byrnes C, Noh SJ, Meier ER, Kim KS, Rabel A, Kaushal M, Muljo SA, Miller JL . LIN28B-mediated expression of fetal hemoglobin and production of fetal-like erythrocytes from adult human erythroblasts ex vivo.. Blood, 2013, 122(6):1034-1041.
[30]	Lohani N, Bhargava N, Munshi A, Ramalingam S . Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders. J Cell Physiol, 2017, doi: 10.1002/jcp.26292.[DOI]
[31]	Capellera-Garcia S, Pulecio J, Dhulipala K, Siva K, Rayon-Estrada V, Singbrant S, Sommarin MNE, Walkley CR, Soneji S, Karlsson G, Raya A, Sankaran VG, Flygare J . Defining the minimal factors required for erythropoiesis through direct lineage conversion. Cell Rep, 2016, 15(11):2550-2562.
[32]	Lucarelli G, Isgrò A, Sodani P, Gaziev J . Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harb Perspect Med, 2012, 2(5):a011825.
[33]	Karponi G, Psatha N, Lederer CW, Adair JE, Zervou F, Zogas N, Kleanthous M, Tsatalas C, Anagnostopoulos A, Sadelain M, Rivière I, Stamatoyannopoulos G, Yannaki E . Plerixafor + G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy . Blood, 2015, 126(5):616-619.
[34]	Yang YY, Zhang XB, Yi L, Hou ZZ, Chen JY, Kou XC, Zhao YH, Wang H, Sun XF, Jiang CZ, Wang YX, Gao SR . Na?ve induced pluripotent stem cells generated from β- thalassemia fibroblasts allow efficient gene correction with CRISPR/Cas9. Stem Cells Transl Med, 2016, 5(1):8-19.
[35]	Song B, Fan Y, He WY, Zhu DT, Niu XH, Wang D, Ou ZH, Luo M, Sun XF . Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system. Stem Cells Dev, 2015, 24(9):1053-1065.
[36]	Xie F, Ye L, Chang JC, Beyer AI, Wang JM, Muench MO, Kan YW . Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res, 2014, 24(9):1526-1533.
[37]	Cornu TI, Mussolino C, Cathomen T . Refining strategies to translate genome editing to the clinic. Nat Med, 2017, 23(4):415-423.
[38]	Hoban MD, Lumaquin D, Kuo CY, Romero Z, Long J, Ho M, Young CS, Mojadidi M, Fitz-Gibbon S, Cooper AR, Lill GR, Urbinati F, Campo-Fernandez B, Bjurstrom CF, Pellegrini M, Hollis RP, Kohn DB . CRISPR/Cas9-mediated correction of the sickle mutation in human CD34+ cells. Mol Ther, 2016, 24(9):1561-1569.
[39]	Ye L, Wang JM, Tan YT, Beyer AI, Xie F, Muench MO, Kan YW . Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: an approach for treating sickle cell disease and β-thalassemia. Proc Natl Acad Sci USA, 2016, 113(38):10661-10665.
[40]	Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S, Steinfeld I, Lunstad BD, Kaiser RJ, Wilkens AB, Bacchetta R, Tsalenko A, Dellinger D, Bruhn L, Porteus MH . Chemically modified guide RNAs enhance CRISPR- Cas genome editing in human primary cells. Nat Biotechnol, 2015, 33(9):985-989.
[41]	Murugan K, Babu K, Sundaresan R, Rajan R, Sashital DG . The revolution continues: newly discovered systems expand the CRISPR-cas toolkit. Mol Cell, 2017, 68(1):15-25.
[42]	Zhang H , McCarty N. CRISPR-Cas9 technology and its application in haematological disorders. Br J Haematol, 2016, 175(2):208-225.

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

β-血红蛋白病基因组编辑治疗的研究进展

Recent advance on genome editing for therapy of β-hemoglobinopathies

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	郑晓飞,黄海燕,吴强. 染色质架构蛋白CTCF调控UGT1基因簇的表达[J]. 遗传, 2019, 41(6): 509-523.
[2]	王珏, 黄娟, 许蕊. 利用CRISPR/Cas9和piggyBac实现果蝇基因组无缝编辑[J]. 遗传, 2019, 41(5): 422-429.
[3]	张楷, 刘蔚, 刘小凤, 陈瑶生, 刘小红, 何祖勇. 利用CRISPR/Cas9系统构建人HPRT1基因定点突变细胞株[J]. 遗传, 2019, 41(10): 939-949.
[4]	刘恒, 李东明, 朱兰玉, 赖乐锦, 闫婉云, 陆玉双, 韦伊, 黄月琪, 方媚, 苏元港, 杨芳, 舒伟. 利用CRISPR/Cas9敲除人源细胞系中LMNA基因的研究[J]. 遗传, 2019, 41(1): 66-75.
[5]	任云晓, 肖茹丹, 娄晓敏, 方向东. 基因编辑技术及其在基因治疗中的应用[J]. 遗传, 2019, 41(1): 18-27.
[6]	张桂珊, 杨勇, 张灵敏, 戴宪华. 机器学习方法在CRISPR/Cas9系统中的应用[J]. 遗传, 2018, 40(9): 704-723.
[7]	刘海龙, 谌阳, 高杨, 周玲, 韩晓松, 赵长志, 杨高娟, 陈毅龙, 杨慧, 谢胜松. 靶向miRNA前体不同类型sgRNA的丰度及特异性评估[J]. 遗传, 2018, 40(7): 561-571.
[8]	唐浚博, 曹浩伟, 许蕊, 张丹丹, 黄娟. 果蝇睾丸基因敲除突变体的构建及表型分析[J]. 遗传, 2018, 40(6): 478-487.
[9]	李慧卿, 陈超, 陈冉冉, 宋雪薇, 李佶娜, 朱延明, 丁晓东. 利用CRISPR/Cas9双基因敲除系统初步解析大豆GmSnRK1.1和GmSnRK1.2对ABA及碱胁迫的响应[J]. 遗传, 2018, 40(6): 496-507.
[10]	鞠君毅,赵权. γ-珠蛋白基因表达调控机制与临床应用[J]. 遗传, 2018, 40(6): 429-444.
[11]	梁彩娇, 孟繁梅, 艾云灿. 基于CRISPR/Cas系统的噬菌体基因组编辑[J]. 遗传, 2018, 40(5): 378-389.
[12]	童晓玲,方春燕,盖停停,石津,鲁成,代方银. CRISPR/Cas9系统在昆虫中的应用[J]. 遗传, 2018, 40(4): 266-278.
[13]	谢晶, 范辰, 张景龙, 张仕强. Ash2l-1/Ash2l-2在小鼠胚胎干细胞中的表达特异性及互补效应[J]. 遗传, 2018, 40(3): 237-249.
[14]	辛高伟, 胡熙璕, 王克剑, 王兴春. Cas9蛋白变体VQR高效识别水稻NGAC前间区序列邻近基序[J]. 遗传, 2018, 40(12): 1112-1119.
[15]	刘旭, 张平, 张晓枫, 李兴, 白宇, 贾克荣, 郭晓东, 张豪, 马晓燕, 仓明, 刘东军, 郭旭东. 利用CRISPR/Cas9系统构建FGF21基因敲除小鼠模型[J]. 遗传, 2018, 40(1): 66-74.